GHRP-2 vs GHRP-6
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Growth Hormone Releasing Peptide 2, Pralmorelin
GHRP-2 (generic name pralmorelin) is a synthetic hexapeptide growth hormone secretagogue and a second-generation cousin of GHRP-6. It prompts the pituitary to release growth hormone and is the one peptide in this family with an actual regulatory approval: it is licensed in Japan as a diagnostic agent for growth hormone deficiency. Outside that narrow diagnostic use it has no approval and is sold elsewhere only as a research compound.
Also: Growth Hormone Releasing Peptide 6, SKF-110679
GHRP-6 is a synthetic six-amino-acid peptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) that tricks the body into releasing its own growth hormone. It was one of the first growth hormone secretagogues ever made, and the hunt to find out why it worked led scientists straight to the discovery of ghrelin. It has no approval as a drug anywhere and is used only as a research compound.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- These GH secretagogues are frequently combined to enhance growth hormone release.
Detailed Comparison
| Attribute | GHRP-2 | GHRP-6 |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Like GHRP-6, GHRP-2 is an agonist at the ghrelin / growth hormone secretagogue receptor (GHS-R1a). Binding that receptor in the pituitary and hypothalamus drives a pulse of growth hormone release. It was designed to be more potent and somewhat cleaner than GHRP-6, with a milder effect on appetite, though it still acts on the ghrelin system so it is not free of off-target hormonal effects. Because it works upstream of the pituitary rather than replacing GH directly, the GH release it causes is still subject to the body's own feedback brakes such as somatostatin. | GHRP-6 binds and activates the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor later found to be the natural target of the hunger hormone ghrelin. When it switches that receptor on in the pituitary and hypothalamus, the pituitary fires off a pulse of growth hormone. Because GHS-R1a also sits on appetite-driving neurons in the brain (the NPY/AgRP cells of the arcuate nucleus), GHRP-6 is a strong appetite stimulant, more so than the other GHRPs. At higher doses it also nudges up cortisol and prolactin, since the receptor system is not perfectly selective for the GH pathway. |
| Common Dosing | 100-300 mcg 2-3x daily 2-3x daily | 100-300 mcg 2-3x daily 2-3x daily |
| Administration | Subcutaneous injection | Subcutaneous injection, ideally fasted |
| Typical Duration | 8-12 weeks | 8-12 weeks |
| Best Time to Take | Before bed or morning (fasted) | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | GHRP-2 has genuine human data behind its diagnostic role. In Japan it reached phase II trials and was approved as pralmorelin (intravenous) to test for growth hormone deficiency, including in children with short stature, making it the only GH secretagogue in this class with any regulatory approval. A published human pharmacology study detected unchanged GHRP-2 and its metabolite AA-3 in the urine of ten male volunteers given the drug intravenously, work driven largely by anti-doping testing because GHRP-2 is banned in sport. What it does NOT have is solid controlled-trial evidence for the body-composition, anti-aging, or recovery uses it is marketed for online. So the honest picture is a real, approved diagnostic tool in one country, with everything beyond that being off-label or unproven research use. | GHRP-6 has been studied in humans, but mostly as a lab and diagnostic probe rather than as a treatment with large clinical trials behind it. Early work in the 1980s and 1990s showed it reliably triggers growth hormone release, and chasing its mechanism is literally what led Kojima and colleagues to discover ghrelin in 1999, which reframed how we understand hunger and GH control. A 2013 pharmacokinetic study in nine healthy men found oral bioavailability under 1 percent and an elimination half-life around 2.5 hours, which is why it is given by injection. The popular claims about muscle gain, fat loss, and healing in fitness circles are not backed by controlled human outcome trials. It is not approved by the FDA or EMA for any use and remains a research chemical, with appetite stimulation, water retention, and cortisol/prolactin bumps as known effects. |
Frequently Asked Questions: GHRP-2 vs GHRP-6
What is the difference between GHRP-2 and GHRP-6?
GHRP-2 is a growth hormone peptide that ghrp-2 (generic name pralmorelin) is a synthetic hexapeptide growth hormone secretagogue and a second-generation cousin of ghrp-6. it prompts the pituitary to release growth hormone and is the one peptide in this family with an actual regulatory approval: it is licensed in japan as a diagnostic agent for growth hormone deficiency. outside that narrow diagnostic use it has no approval and is sold elsewhere only as a research compound. GHRP-6 is a growth hormone peptide that ghrp-6 is a synthetic six-amino-acid peptide (his-d-trp-ala-trp-d-phe-lys-nh2) that tricks the body into releasing its own growth hormone. it was one of the first growth hormone secretagogues ever made, and the hunt to find out why it worked led scientists straight to the discovery of ghrelin. it has no approval as a drug anywhere and is used only as a research compound. The main differences lie in their mechanisms of action and clinical applications.
Which is better, GHRP-2 or GHRP-6?
Neither is universally "better" - the choice depends on your specific goals. GHRP-2 is typically used for growth hormone purposes, while GHRP-6 is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can GHRP-2 and GHRP-6 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using GHRP-2 and GHRP-6 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.